

Endo Pharmaceuticals Solutions Inc.  
Form 8-K  
March 25, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 25, 2009 (March 25, 2009)**

**Endo Pharmaceuticals Solutions Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-18728**  
(Commission File Number)

**100 Endo Boulevard**

**Chadds Ford, Pennsylvania 19317**

**04-3047911**  
(IRS Employer

Identification Number)

Edgar Filing: Endo Pharmaceuticals Solutions Inc. - Form 8-K

(Address of principal executive offices)

**Registrant's telephone number, including area code:**

**(610-558-9800)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On March 25, 2009, Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.) issued a press release announcing the commencement of an offer to purchase its 6.25% Convertible Senior Notes due 2009, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release of Endo, dated March 25, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Endo Pharmaceuticals Solutions Inc.  
(Registrant)

By: /s/ Caroline B. Manogue

Name: Caroline B. Manogue  
Title: Executive Vice President, Chief Legal Officer  
and Secretary

Dated: March 25, 2009

INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release of Endo, dated March 25, 2009